Trial Profile
A Phase II Study Of Cabazitaxel For Metastatic Gastroesophageal Adenocarcinomas That Have Relapsed After At Least One Line Of Chemotherapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 22 Jun 2018
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 14 Dec 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 21 Sep 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 07 Jun 2011 New trial record